OR WAIT 15 SECS
Kevin Gopal is Pharmaceutical Executive's international correspondent, covering pharma and regulatory issues around the word. He is also a political columnist for North West Business Insider, one of the UK's leading regional business magazines. He started his career as a journalist at SiYu, the UK's Chinese community magazine, before joining the PE staff.
London/Sodertalje—AstraZeneca’s decision to drop Viozan (AR-C68397AA) for chronic obstructive pulmonary disease (COPD) could be GlaxoSmithKline’s gain.